Perflubron | CAS#423-55-2 | anti-obesity compound

MedKoo Cat#: 598973 | Name: Perflubron

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Perflubron is a potential anti-obesity compound; reduces food adsorption; 8-carbon perfluorocarbon radiopaque compound; an oral contrast agent for use with MRI to enhance delineation of the bowel distinguishing it from adjacent organs.

Chemical Structure

Perflubron

CAS#423-55-2

Theoretical Analysis

MedKoo Cat#: 598973

Name: Perflubron

CAS#: 423-55-2

Chemical Formula: C8BrF17

Exact Mass: 497.8912

Molecular Weight: 498.96

Elemental Analysis: C, 19.26; Br, 16.01; F, 64.73

Price and Availability

Size	Price	Availability
5g	USD 350.00	2 Weeks
25g	USD 950.00	2 Weeks
50g	USD 1,450.00	2 Weeks
100g	USD 2,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Perflubron; Oxygent; Long's compound; Imagent GI; Imagent; LiquiVent; Perfluoroctyl bromide;

IUPAC/Chemical Name

1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane

InChi Key

WTWWXOGTJWMJHI-UHFFFAOYSA-N

InChi Code

InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26

SMILES Code

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(Br)F

Appearance

Liquid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# O22W05C09

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Perflubron(1-Bromoheptadecafluorooctane;Heptadecafluorooctyl bromide; Perfluorooctyl bromide) is a contrast medium for magnetic resonance imaging and sonography.

In vitro activity:

Alveolar macrophages were stimulated for 1 hr with lipopolysaccharide and then treated with perflubron for 23 hrs. Tumor necrosis factor-alpha, interleukin-1, and interleukin-6 were stimulated by lipopolysaccharide (endotoxin) and all of these cytokines were significantly (p < .05) inhibited by perflubron. Reference: Crit Care Med. 1997 Dec;25(12):2045-7. https://pubmed.ncbi.nlm.nih.gov/9403756/

In vivo activity:

Corneal staining scores of DED (dry eye disease) rabbits respectively treated by ATS, PFOB@LIP-ATS, Tet-ATS and PFOB@LIP-Tet-ATS for seven days were 3.7±0.5, 3.2±0.4, 1.5±0.5 and 0.5±0.5. The expressions of related cytokines were correspondingly downregulated significantly, indicating that the inflammation of DED was successfully suppressed. The intraocular pressure changes of DED rabbits before and after treatment by PFOB@LIP-Tet showed no statistical significance. Reference: Int J Nanomedicine. 2021 May 26;16:3613-3631. https://pubmed.ncbi.nlm.nih.gov/34079253/

	Solvent	mg/mL	mM
Solubility
	DMSO	16.7	33.41

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 498.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Rotta AT, Gunnarsson B, Fuhrman BP, Wiryawan B, Hernan LJ, Steinhorn DM. Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems. Pediatr Crit Care Med. 2003 Apr;4(2):233-8. doi: 10.1097/01.PCC.0000059729.21375.D0. PMID: 12749658. 2. Thomassen MJ, Buhrow LT, Wiedemann HP. Perflubron decreases inflammatory cytokine production by human alveolar macrophages. Crit Care Med. 1997 Dec;25(12):2045-7. doi: 10.1097/00003246-199712000-00023. PMID: 9403756. 3. Huang L, Gao H, Wang Z, Zhong Y, Hao L, Du Z. Combination Nanotherapeutics for Dry Eye Disease Treatment in a Rabbit Model. Int J Nanomedicine. 2021 May 26;16:3613-3631. doi: 10.2147/IJN.S301717. PMID: 34079253; PMCID: PMC8165218. 4. Luo S, Ding J, Wang P, Wang Z, Ma X, Yang C, Liang Q, Rong P, Wang W. Carboxyl of Poly(D,L-lactide-co-glycolide) Nanoparticles of Perfluorooctyl Bromide for Ultrasonic Imaging of Tumor. Contrast Media Mol Imaging. 2018 Feb 7;2018:2957459. doi: 10.1155/2018/2957459. PMID: 29568245; PMCID: PMC5820656.

In vitro protocol:

In vivo protocol:

1. Huang L, Gao H, Wang Z, Zhong Y, Hao L, Du Z. Combination Nanotherapeutics for Dry Eye Disease Treatment in a Rabbit Model. Int J Nanomedicine. 2021 May 26;16:3613-3631. doi: 10.2147/IJN.S301717. PMID: 34079253; PMCID: PMC8165218. 2. Luo S, Ding J, Wang P, Wang Z, Ma X, Yang C, Liang Q, Rong P, Wang W. Carboxyl of Poly(D,L-lactide-co-glycolide) Nanoparticles of Perfluorooctyl Bromide for Ultrasonic Imaging of Tumor. Contrast Media Mol Imaging. 2018 Feb 7;2018:2957459. doi: 10.1155/2018/2957459. PMID: 29568245; PMCID: PMC5820656.

1: Mychaliska G, Bryner B, Dechert R, Kreutzman J, Becker M, Hirschl R. Safety and efficacy of perflubron-induced lung growth in neonates with congenital diaphragmatic hernia: Results of a prospective randomized trial. J Pediatr Surg. 2015 Jul;50(7):1083-7. doi: 10.1016/j.jpedsurg.2015.03.004. Epub 2015 Mar 13. PubMed PMID: 25799085. 2: El Mays TY, Choudhury P, Leigh R, Koumoundouros E, Van der Velden J, Shrestha G, Pieron CA, Dennis JH, Green FH, Snibson KJ. Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma. Respir Res. 2014 Sep 16;15:98. doi: 10.1186/s12931-014-0098-x. PubMed PMID: 25355286; PubMed Central PMCID: PMC4172894. 3: Shah M, Phillips MR, Bryner B, Hirschl RB, Mychaliska GB, McLean SE. Effect of Perflubron-induced lung growth on pulmonary vascular remodeling in congenital diaphragmatic hernia. Pediatr Surg Int. 2016 Jun;32(6):583-90. doi: 10.1007/s00383-016-3887-0. Epub 2016 Mar 23. PubMed PMID: 27008334; PubMed Central PMCID: PMC5171210. 4: Scholz AW, Eberle B, Heussel CP, David M, Schmittner MD, Quintel M, Schreiber LM, Weiler N. Ventilation-perfusion ratio in perflubron during partial liquid ventilation. Anesth Analg. 2010 Jun 1;110(6):1661-8. doi: 10.1213/ANE.0b013e3181d3e1d5. Epub 2010 May 6. PubMed PMID: 20448078. 5: Curtis SE, Peek JT, Kelly DR. Partial liquid breathing with perflubron improves arterial oxygenation in acute canine lung injury. J Appl Physiol (1985). 1993 Dec;75(6):2696-702. PubMed PMID: 8125892. 6: Thomassen MJ, Buhrow LT, Wiedemann HP. Perflubron decreases inflammatory cytokine production by human alveolar macrophages. Crit Care Med. 1997 Dec;25(12):2045-7. PubMed PMID: 9403756. 7: Noveck RJ, Shannon EJ, Leese PT, Shorr JS, Flaim KE, Keipert PE, Woods CM. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth Analg. 2000 Oct;91(4):812-22. PubMed PMID: 11004031. 8: Shepherd AP, Steinke JM. CO-oximetry interference by perflubron emulsion: comparison of hemolyzing and nonhemolyzing instruments. Clin Chem. 1998 Oct;44(10):2183-90. PubMed PMID: 9761254. 9: Kishioka C, Dorighi MP, Rubin BK. Perfluorooctyl bromide (perflubron) stimulates mucin secretion in the ferret trachea. Chest. 1999 Mar;115(3):823-8. PubMed PMID: 10084498. 10: Weiss DJ, Baskin GB, Shean MK, Blanchard JL, Kolls JK. Use of perflubron to enhance lung gene expression: safety and initial efficacy studies in non-human primates. Mol Ther. 2002 Jan;5(1):8-15. PubMed PMID: 11786040. 11: Rotta AT, Gunnarsson B, Fuhrman BP, Wiryawan B, Hernan LJ, Steinhorn DM. Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems. Pediatr Crit Care Med. 2003 Apr;4(2):233-8. PubMed PMID: 12749658. 12: André MP, Steinbach G, Mattrey RF. Enhancement of the echogenicity of flowing blood by the contrast agent perflubron. Invest Radiol. 1993 Jun;28(6):502-6. PubMed PMID: 8320067. 13: Rempf C, Standl T, Gottschalk A, Freitag M, Ritter A, Lang E, Tuszynski S, Burmeister MA. Effects of a prophylactic or therapeutic application of perflubron emulsion on myocardial ischaemia-reperfusion injury in rats. Eur J Anaesthesiol. 2008 Oct;25(10):850-9. doi: 10.1017/S0265021508004596. Epub 2008 Jun 9. PubMed PMID: 18538048. 14: Spahn DR, van Brempt R, Theilmeier G, Reibold JP, Welte M, Heinzerling H, Birck KM, Keipert PE, Messmer K, Heinzerling H, Birck KM, Keipert PE, Messmer K. Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group. Anesthesiology. 1999 Nov;91(5):1195-208. PubMed PMID: 10551568. 15: Leese PT, Noveck RJ, Shorr JS, Woods CM, Flaim KE, Keipert PE. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. Anesth Analg. 2000 Oct;91(4):804-11. PubMed PMID: 11004030. 16: Mattrey RF, Trambert MA, Brown JJ, Young SW, Bruneton JN, Wesbey GE, Balsara ZN. Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial. Radiology. 1994 Jun;191(3):841-8. PubMed PMID: 8184076. 17: Flores-Aguilar M, Munguia D, Loeb E, Crapotta JA, Vuong C, Shakiba S, Bergeron-Lynn G, Wiley CA, Weers J, Freeman WR. Intraocular tolerance of perfluorooctylbromide (perflubron). Retina. 1995;15(1):3-13. PubMed PMID: 7754245. 18: Nolte D, Pickelmann S, Lang M, Keipert P, Messmer K. Compatibility of different colloid plasma expanders with perflubron emulsion: an intravital microscopic study in the hamster. Anesthesiology. 2000 Nov;93(5):1261-70. PubMed PMID: 11046215. 19: Rosen NA, Hopf HW, Hunt TK. Perflubron emulsion increases subcutaneous tissue oxygen tension in rats. Wound Repair Regen. 2006 Jan-Feb;14(1):55-60. PubMed PMID: 16476072. 20: Smith DJ, Lane TA. Effect of high concentration perflubron emulsion on platelet function. Biomater Artif Cells Immobilization Biotechnol. 1993;21(2):173-81. PubMed PMID: 8318610.